PRL and prostate carcinoma: The enriched pathways were categorized, and 10 highly associated pathways were selected as follows: lipid and atherosclerosis (hsa05417), EGFR tyrosine kinase inhibitor resistance (hsa01521), neuroactive ligand-receptor interaction(hsa04080), prolactin signaling pathway (hsa04917), apoptosis (hsa04210), AGE-RAGE signaling pathway in diabetic complications (hsa04933), insulin resistance (hsa04931), prostate cancer (hsa05215), chemical carcinogenesis-receptor activation (hsa05207), and endocrine resistance (hsa01522).